H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best Robinhood penny stocks to invest in. The stock has shown strong momentum, rallying by more than 100% year to date. Likewise, on August 19, analysts at H.C. Wainwright reiterated a ‘Buy’ rating on the stock with a $10 price target.

The research firm’s positive stance is based on the anticipation of key clinical data expected early next year. It has already conducted a literature review of seralutinib, the company’s investigational drug for pulmonary arterial hypertension, and affirmed its positive outlook.

Data review from a Phase 2 TORREY trial underscored sustained hemodynamic and functional improvements through 72 weeks of treatment. Additionally, the trial demonstrated a continued reduction in pulmonary vascular resistance and an improvement in six-minute walk distance among patients. The research firm is optimistic that Gossamer will deliver a positive Phase 3 PROSERA trial, which will affirm the drug’s potential as a disease-modifying therapy.

Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for rare diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Cybersecurity Stocks to Buy Right Now and 10 Best American Mining Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.